Specialized and personalized drugs are among the fastest growing segments in the pharmaceutical market. A significant growth in therapies targeting rare and orphan diseases has resulted in an increase in high-value, lower-volume drug products, which require more flexible, automated packaging processes. Sharp, a global leader in contract packaging and clinical supply services, has been quick to respond to this trend in support of their clients across the biotech industry. Their sustained demand for small lot packaging capacities expanded Sharp’s focus on long-running, high-volume packaging processes to include efficient, flexible, and highly automated packaging of smaller batches combined with multi-component kitting. The company, which is part of UDG Healthcare plc, has lately announced a further investment of $10M in equipment capabilities to directly support client demand in the biologics and injectables market. Part of this investment are two Dividella NeoTOP x toploading machines from Körber’s Business Area Pharma.